These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38082255)

  • 41. Whole-Brain Magnetic Resonance Spectroscopy Reveals Distinct Alterations in Neurometabolic Profile in Progressive Supranuclear Palsy.
    Klietz M; Mahmoudi N; Maudsley AA; Sheriff S; Bronzlik P; Almohammad M; Nösel P; Wegner F; Höglinger GU; Lanfermann H; Ding XQ
    Mov Disord; 2023 Aug; 38(8):1503-1514. PubMed ID: 37289057
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Differentiating progressive supranuclear palsy from Parkinson's disease by MRI-based dynamic cerebrospinal fluid flow.
    Fukui Y; Hishikawa N; Sato K; Yunoki T; Kono S; Matsuzono K; Nakano Y; Ohta Y; Yamashita T; Deguchi K; Abe K
    J Neurol Sci; 2015 Oct; 357(1-2):178-82. PubMed ID: 26227830
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Predicting the Progression of Parkinson's Disease MDS-UPDRS-III Motor Severity Score from Gait Data using Deep Learning.
    Zia Ur Rehman R; Rochester L; Yarnall AJ; Del Din S
    Annu Int Conf IEEE Eng Med Biol Soc; 2021 Nov; 2021():249-252. PubMed ID: 34891283
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Apparent diffusion coefficient of the superior cerebellar peduncle differentiates progressive supranuclear palsy from Parkinson's disease.
    Nicoletti G; Tonon C; Lodi R; Condino F; Manners D; Malucelli E; Morelli M; Novellino F; Paglionico S; Lanza P; Messina D; Barone P; Morgante L; Zappia M; Barbiroli B; Quattrone A
    Mov Disord; 2008 Dec; 23(16):2370-6. PubMed ID: 18816803
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Distinct patterns of brain activity in progressive supranuclear palsy and Parkinson's disease.
    Burciu RG; Ofori E; Shukla P; Planetta PJ; Snyder AF; Li H; Hass CJ; Okun MS; McFarland NR; Vaillancourt DE
    Mov Disord; 2015 Aug; 30(9):1248-58. PubMed ID: 26148135
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Magnetic Resonance Parkinsonism Index and midbrain to pons ratio: Which index better distinguishes Progressive Supranuclear Palsy patients with a low degree of diagnostic certainty from patients with Parkinson Disease?
    Nigro S; Morelli M; Arabia G; Nisticò R; Novellino F; Salsone M; Rocca F; Quattrone A
    Parkinsonism Relat Disord; 2017 Aug; 41():31-36. PubMed ID: 28487107
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development and Validation of Automated Magnetic Resonance Parkinsonism Index 2.0 to Distinguish Progressive Supranuclear Palsy-Parkinsonism From Parkinson's Disease.
    Quattrone A; Bianco MG; Antonini A; Vaillancourt DE; Seppi K; Ceravolo R; Strafella AP; Tedeschi G; Tessitore A; Cilia R; Morelli M; Nigro S; Vescio B; Arcuri PP; De Micco R; Cirillo M; Weis L; Fiorenzato E; Biundo R; Burciu RG; Krismer F; McFarland NR; Mueller C; Gizewski ER; Cosottini M; Del Prete E; Mazzucchi S; Quattrone A
    Mov Disord; 2022 Jun; 37(6):1272-1281. PubMed ID: 35403258
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prediagnostic motor and non-motor symptoms in progressive supranuclear palsy: The step-back PSP study.
    Painous C; Martí MJ; Simonet C; Garrido A; Valldeoriola F; Muñoz E; Cámara A; Compta Y
    Parkinsonism Relat Disord; 2020 May; 74():67-73. PubMed ID: 32536421
    [TBL] [Abstract][Full Text] [Related]  

  • 49. "Parkinson's disease" on the way to progressive supranuclear palsy: a review on PSP-parkinsonism.
    Necpál J; Borsek M; Jeleňová B
    Neurol Sci; 2021 Dec; 42(12):4927-4936. PubMed ID: 34532773
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The genetic and clinico-pathological profile of early-onset progressive supranuclear palsy.
    Jabbari E; Woodside J; Tan MMX; Pavese N; Bandmann O; Ghosh BCP; Massey LA; Capps E; Warner TT; Lees AJ; Revesz T; Holton JL; Williams NM; Grosset DG; Morris HR
    Mov Disord; 2019 Sep; 34(9):1307-1314. PubMed ID: 31299107
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Diagnosis Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Syndrome.
    Jabbari E; Holland N; Chelban V; Jones PS; Lamb R; Rawlinson C; Guo T; Costantini AA; Tan MMX; Heslegrave AJ; Roncaroli F; Klein JC; Ansorge O; Allinson KSJ; Jaunmuktane Z; Holton JL; Revesz T; Warner TT; Lees AJ; Zetterberg H; Russell LL; Bocchetta M; Rohrer JD; Williams NM; Grosset DG; Burn DJ; Pavese N; Gerhard A; Kobylecki C; Leigh PN; Church A; Hu MTM; Woodside J; Houlden H; Rowe JB; Morris HR
    JAMA Neurol; 2020 Mar; 77(3):377-387. PubMed ID: 31860007
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Eye tracking identifies biomarkers in α-synucleinopathies versus progressive supranuclear palsy.
    Habibi M; Oertel WH; White BJ; Brien DC; Coe BC; Riek HC; Perkins J; Yep R; Itti L; Timmermann L; Best C; Sittig E; Janzen A; Munoz DP
    J Neurol; 2022 Sep; 269(9):4920-4938. PubMed ID: 35501501
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combining quantitative susceptibility mapping to the morphometric index in differentiating between progressive supranuclear palsy and Parkinson's disease.
    Azuma M; Hirai T; Nakaura T; Kitajima M; Yamashita S; Hashimoto M; Yamada K; Uetani H; Yamashita Y; Wang Y
    J Neurol Sci; 2019 Nov; 406():116443. PubMed ID: 31634718
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Understanding the relationship between freezing of gait and other progressive supranuclear palsy features.
    Rezvanian S; Litvan I; Standaert D; Jankovic J; Reich SG; Hall D; Shprecher DR; Bordelon Y; Dubinsky R; Kluger B
    Parkinsonism Relat Disord; 2020 Sep; 78():56-60. PubMed ID: 32731191
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Quantifying Parkinson's disease severity using mobile wearable devices and machine learning: the ParkApp pilot study protocol.
    Ymeri G; Salvi D; Olsson CM; Wassenburg MV; Tsanas A; Svenningsson P
    BMJ Open; 2023 Dec; 13(12):e077766. PubMed ID: 38154904
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy.
    Schirinzi T; Sancesario GM; Di Lazzaro G; Scalise S; Colona VL; Imbriani P; Mercuri NB; Bernardini S; Lang AE; Pisani A
    J Neural Transm (Vienna); 2018 Sep; 125(9):1373-1379. PubMed ID: 29948175
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of gait in progressive supranuclear palsy, Parkinson's disease and healthy older adults.
    Egerton T; Williams DR; Iansek R
    BMC Neurol; 2012 Oct; 12():116. PubMed ID: 23031506
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The combination of short-step and wide-based gait is a gait characteristic in progressive supranuclear palsy: a retrospective, cross-sectional study.
    Takamatsu Y; Matsuda N; Aiba I
    Eur Geriatr Med; 2019 Oct; 10(5):809-815. PubMed ID: 34652693
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sensor-based gait analysis in atypical parkinsonian disorders.
    Raccagni C; Gaßner H; Eschlboeck S; Boesch S; Krismer F; Seppi K; Poewe W; Eskofier BM; Winkler J; Wenning G; Klucken J
    Brain Behav; 2018 Jun; 8(6):e00977. PubMed ID: 29733529
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A network approach to diagnostic biomarkers in progressive supranuclear palsy.
    Santiago JA; Potashkin JA
    Mov Disord; 2014 Apr; 29(4):550-5. PubMed ID: 24347522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.